Grok 4 Launch Breakdown, OpenAI to Release Web Browser | Chris Paik, Will Bruey, Joel Becker, Dylan Parker, Eric Olson, Ghita Houir Alami, Elliot Hershberg, Karim Atiyeh
TBPN
00:00
The Future of Biotech: Opportunities and Challenges
This chapter explores the transformative role of biotechnology and AI in drug discovery and investment trends within the sector. It balances optimism for a new era in biotech with a cautionary note on the need for genuine innovation amidst marketing hype.
Transcript
Play full episode
Transcript
Episode notes
- (02:28) - Grok 4 Launch Breakdown
- (36:09) - Open AI to Release Web Browser
- (50:31) - Apple Plans to Release New Apple Vision Pro Model
- (58:48) - Chris Paik, General Partner at Pace Capital and former Partner at Thrive Capital, discusses the evolution of human-computer interaction, emphasizing the potential of technologies like eye tracking and gesture recognition. He explores the rise of VTubing and YouTube's impact on digital content, highlighting how virtual avatars are reshaping the creator landscape. Paik also introduces the "atomic value swap" framework for assessing market fit and business model alignment, stressing the importance of balanced value exchanges to ensure platform success.
- (01:33:50) - Will Bruey, co-founder and CEO of Varda Space Industries, discusses how microgravity enables the creation of pharmaceutical formulations not possible on Earth, as gravity affects crystal growth and particle size distribution. By manufacturing drugs in space, Varda aims to produce purer and more uniform medications, potentially improving patient outcomes. Bruey also outlines the company's plans to scale up production and establish reentry sites globally to meet the growing demand for space-manufactured pharmaceuticals.
- (01:53:02) - Joel Becker, a researcher at Meta, discusses a study evaluating the impact of AI assistance on experienced open-source developers working on large, long-standing projects. Contrary to expectations, the study found that developers who used AI tools were actually slowed down, rather than sped up. Becker emphasizes the need for further research to understand these findings and to assess the potential for AI systems to autonomously improve their own capabilities.
- (02:13:07) - Dylan Parker, Co-Founder and CEO of Moment, discusses his company's recent $36 million Series B funding led by Index Ventures, the evolution of fixed income trading from manual to electronic systems, and Moment's role in providing modern fixed income infrastructure for financial institutions, including a partnership with LPL Financial.
- (02:22:35) - Eric Olson, co-founder and CEO of Consensus, an AI-powered search engine for academic research, discusses how Consensus leverages large language models to provide researchers with faster, evidence-based answers from peer-reviewed journals. He highlights the platform's dedicated focus on academic content, enabling more intelligent searches and citation-forward interfaces tailored for researchers. Olson also addresses the challenges of accessing paywalled content and emphasizes the importance of open access to scientific literature.
- (02:33:27) - Ghita Houir Alami, co-founder of ZeroEntropy, holds two master's degrees in applied mathematics from École Polytechnique and UC Berkeley. She discusses her journey from computer vision to large language models, leading to the creation of ZeroEntropy, which focuses on enhancing retrieval systems for AI by building search tools for Retrieval-Augmented Generation (RAG) and agents. Alami emphasizes the importance of precise and efficient retrieval to prevent AI hallucinations and highlights the company's recent release of a reranker model to improve search accuracy.
- (02:42:53) - Elliot Hershberg is a biotech scientist, writer, and investor who has contributed to cancer vaccine design, developed computational tools for spatial genomics, and worked on genome browser software. He authors the "Century of Biology" newsletter and has served as Biotech Partner at Not Boring Capital, focusing on synthetic biology investments. In the conversation, Hershberg discusses the integration of artificial intelligence in biotechnology, highlighting its transformative impact on drug discovery and the development of innovative medicines.
- (02:52:22) - Karim Atiyeh, co-founder and CTO of Ramp, discusses the launch of Ramp's first AI agent designed to streamline corporate expense management by automating decisions between finance teams and other departments. This agent, knowledgeable about company expense policies and transaction details, reduces the need for manual approvals and enhances efficiency. Atiyeh also highlights the agent's ability to gather contextual information from various sources, such as calendars and emails, to make informed decisions, thereby minimizing delays and improving compliance.
TBPN.com is made possible by:
Ramp - https://ramp.com
Figma - https://figma.com
Vanta - https://vanta.com
Linear - https://linear.app
Eight Sleep - https://eightsleep.com/tbpn
Wander - https://wander.com/tbpn
Public - https://public.com
AdQuick - https://adquick.com
Bezel - https://getbezel.com
Numeral - https://www.numeralhq.com
Polymarket - https://polymarket.com
Attio - https://attio.com/tbpn
Fin - https://fin.ai/tbpn
Graphite - https://graphite.dev
Follow TBPN:
https://TBPN.com
https://x.com/tbpn
https://open.spotify.com/show/2L6WMqY3GUPCGBD0dX6p00?si=674252d53acf4231
https://podcasts.apple.com/us/podcast/technology-brothers/id1772360235
https://www.youtube.com/@TBPNLive
The AI-powered Podcast Player
Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
